
Trump's HIV funding cuts will also exacerbate diabetes, cervical cancer and depression
The impact of US President Donald Trump's administration slashing more than half of South Africa's HIV and TB projects, transcends reduced access to HIV testing and HIV prevention and treatment drugs: treatment for noncommunicable diseases (NCDs) will become harder to come by too.
As government clinics take on HIV patients who were previously treated by the President's Emergency Plan sor Aids Relief-funded projects, the treatment of diseases like diabetes and heart disease — for all people — will come under pressure.
And mental health issues such as depression and anxiety — also noncommunicable illnesses — will most likely become more common among people with HIV, because many now face extra stress, such as having to travel further to clinics for treatment, and groups like sex workers increasingly face discrimination at government clinics.
At a Bhekisisa and Southern African HIV Clinicians Society webinar in May, the health advocacy organisation Treatment Action Campaign (TAC) and the sex worker movement Sisonke, for example, reported cases where sex workers — who used to get their treatment from US government-funded clinics where health workers were trained to address their reproductive health needs — have recently been turned away from state clinics or were denied condoms.
In 2020, noncommunicable diseases were the cause of more than half of all deaths in South Africa. But, compared to HIV, funding for noncommunicable diseases has traditionally been scarce.
We look at five ways in which HIV funding cuts could affect noncommunicable diseases.
Fewer data capturers means fewer people to keep track of NCDs
Today, people over 50 make up the second-largest group of South Africa's HIV-positive population, Bhekisisa's data team has found. Twenty years ago, they were the smallest proportion.
As people age, their chances of developing health problems like high blood pressure, heart disease and diabetes rise, which means more and more people will have to be treated for these conditions — on top of getting HIV care.
Because antiretroviral drugs (ARVs) keep people healthy and increase their life expectancy, the scale-up of treatment in South Africa — public sector treatment started in 2004 and in 2025 we've got about six million people on ARVs — means that most people with HIV and who take ARVs correctly now live just as long as those without the virus.
So, as the peak of the HIV-infected population shifts into an older age band, more and more people will probably have to be treated for noncommunicable diseases like heart conditions, diabetes, overweight and high blood pressure — on top of receiving HIV care.
Studies have shown that people with HIV who are older than 50 have double the chance of having conditions like diabetes or high blood pressure than younger HIV-positive people.
But without tracking the numbers — which will be challenging with the loss of thousands of US government-funded data capturers in the wake of foreign aid cuts — putting plans in place to care for an ageing HIV population will be hard.
And with many countries' governments, including South Africa's, scrambling to find the money to replace the thousands of data capturers for HIV programmes previously funded by the US government after the abrupt halt in aid, funds for tracking the health conditions of older people with HIV will probably be a low priority.
Employing health workers to capture and manage health data would be a hard sell, said Kate Rees, a public health specialist with the Anova Health Institute, during the Bhekisisa and the Southern African HIV Clinicians Society webinar — something that, for a public health issue that might be ignored because its fallout wasn't immediately visible — could just make the problem so much worse.
Fewer people on ARVs leads to more people with diabetes
When people with HIV are not on treatment, or if they don't use their ARVs correctly, the virus gets a chance to make copies of itself in their bodies and attack their immune systems.
That's when their immune systems get weak, and some then fall ill with diseases that scientists call opportunistic infections. The most common opportunistic infection for people with untreated HIV is tuberculosis (TB).
And that's where the catch for one of the world's fastest-rising noncommunicable diseases, diabetes, lies: there's a link between TB and diabetes.
Diabetes — a condition in which someone has too much sugar in their blood because their body doesn't get or respond to the signal from the hormone insulin to absorb glucose — kills more people in South Africa than any other disease. In 2020, it claimed 32,100 lives — about 40% of them before they turned 65.
The condition is one of four noncommunicable diseases World Health Organization (WHO) member countries agreed to tackle. The goal is to lower deaths by 25% by the end of this year.
But South Africa is far off track and that goal will now be even harder to achieve.
TB changes how someone's body reacts to insulin. That's why some people with TB — who have never been diagnosed with diabetes — are found to have lots of sugar in their blood. In some cases, this is temporary and normalises after TB treatment. But the germ still increases the odds of developing diabetes later on.
In fact, among people who have high sugar levels in their blood when getting diagnosed for TB, studies show that between 8% and 87% are eventually diagnosed with diabetes.
But, the opposite is also true: people with diabetes have a higher chance of falling ill with TB.
So, in short: when there's less money to help people with HIV get diagnosed or to make it easy for diagnosed people to get on to treatment, and stick to it, more people get TB. And when more people have TB, diabetes becomes more common, because some people with TB are more likely to get diabetes. At the same time, people with diabetes who get TB, have a higher chance of falling very ill with TB, because diabetes makes their immune systems even weaker.
Fewer women on ARVs means more with cervical cancer
Last week, the Clinical HIV Research Unit at Wits University in Johannesburg shut its cervical cancer screening and prevention clinic at Helen Joseph Hospital, one of the biggest units in the country, following the termination of US funding.
'This closure will significantly impact cervical cancer prevention efforts in South Africa, which faces one of the highest rates of cervical cancer in the world,' the unit said in a press release.
Cervical cancer is the second most common cancer among South African women, after breast cancer, but it's the leading cause of cancer-related deaths — even though it's preventable through vaccination and regular screenings such as pap smears and testing for the human papillomavirus (HPV), which causes most cervical cancer cases.
'With timely screening and early detection being key to preventing cervical cancer, the closure of this screening unit at Helen Joseph Hospital leaves a major gap in services and will further strain the health service,' the unit's communication department said.
Women with untreated HIV infection are much more likely to develop cervical cancer after being infected with cancerous forms of the HPV virus, because their immune systems are too weak to clear the virus without treatment.
Cervical cancer is the most common cancer among black South African women, who are also the group with the highest HIV infection rate in the country.
About a quarter of people with HIV in South Africa are not on antiretroviral treatment. USAid programmes that have now been discontinued helped to find them by sending community health workers into communities to test people for HIV and find people who had already been diagnosed with HIV, but fell off treatment.
The ending of USAid programmes has resulted in fewer HIV testing and treatment services, which in turn affects how many women become vulnerable to developing cervical cancer.
Depression and anxiety will become more common
Mental health conditions are also noncommunicable diseases.
If more people with HIV are left without treatment as a result of US government funding cuts, mental health conditions like depression and anxiety will likely become more common.
Why? Because Pepfar funded counsellors who would find people with HIV and get them on treatment immediately after they were tested.
Without ART, some people develop HIV encephalopathy, a condition that damages brain tissue through inflammation from the virus. Encephalopathy raises the chances of depression or anxiety because it harms the areas of the brain that control movement, emotions and memory.
People with HIV already face stigma that causes stress and anxiety that can lead to depression.
'There's still the shame, stigma and moral issues that come with HIV,' says Francois Venter, an HIV doctor and the director of Ezintsha at the University of the Witwatersrand.
Depression makes it harder for people to stick to their treatment. Studies show that people with HIV and depression are more likely to stop taking their medication — weakening their bodies and raising the chances of them dying from opportunistic infections.
Fewer nurses means noncommunicable diseases fall through the cracks
Noncommunicable diseases are underdiagnosed in South Africa, experts say.
'If we went into the community aggressively looking for high sugar and blood pressure, we would do such a better job,' says Venter. 'Instead, we sit back and wait([until people turn up at clinics), which is why we do so badly with diabetes and hypertension.'
Even at clinics, people are rarely tested, mostly because there are too few nurses at our clinics. On top of noncommunicable diseases, they also have to help treat HIV and gender-based violence, and see that pregnant women and newborn babies are healthy.
And after February's US funding cuts, we have even fewer nurses. According to health department data, Pepfar funded 2,320 nurses, of which just over half (those programmes that received their funds through USAid) have now been laid off. Right now, the rest (programmes funded through the Centres for Disease Control and Prevention), only have jobs until the end of September.
Pepfar also funded 2,705 lay counsellors, health department data shows. Without this staff who went into communities to screen people for HIV, TB and other diseases, patients now have to travel to clinics for help, which means more patients for nurses.
And when nurses have more work, they have less time to treat each patient, which, says Venter, makes it even harder to pick up on noncommunicable diseases.
'Because of that, the actual interaction would take probably an hour and a half. When you've got a mile-long queue outside your door, you just don't have that time.'
'So they (nurses) go for the absolute basic stuff.' DM
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Maverick
17 hours ago
- Daily Maverick
Promising new monthly pill moves to phase-three trials in HIV prevention revolution
A new antiretroviral pill has shown promising results and is now entering large-scale trials. Spotlight reports on new findings on the pill. There are several antiretroviral formulations proven to prevent HIV infection: a daily pill, two different jabs that offer protection for two and six months, respectively, and a vaginal ring for women that has to be replaced monthly. In a few years, a long-acting pill may join the ranks, if it works. The pill, for now called MK-8527, has the potential to prevent HIV infection for up to a month in its current formulation. It is a nucleoside reverse transcriptase translocation inhibitor, which means it disrupts a specific step in the cycle by which the virus makes copies of itself. The pill is now moving on to pivotal phase-three trials after promising results from a smaller phase-two study presented at the International Aids Society (IAS) conference held in Kigali, Rwanda. The phase-two study, conducted in trial sites in South Africa, the US and Israel, showed that MK-8527 was well tolerated and had a safety profile similar to a placebo. It also showed the levels of the antiretroviral were at the required levels in participants' bodies, although the study was not designed to determine whether it is effective. Whether MK-8527 actually prevents HIV infection will now be tested in two large phase-three studies in multiple countries, including South Africa. In these studies, the efficacy of the monthly pill will be compared with that of a daily HIV prevention pill already widely available in South Africa's public sector. The daily pill contains the antiretroviral drugs tenofovir disoproxil fumarate and emtricitabine. Latest findings The phase-two study looked at three different doses of the monthly pill – 3mg, 6mg and 12mg – as well as a placebo. The 350 participants, about one third of whom were from South Africa, were given one pill (either an active pill or placebo) every month for six months. They were monitored for at least two months afterwards. None of the participants acquired HIV during the study. The researchers enrolled adults who were at a low risk of being exposed to HIV and excluded pregnant and breast-feeding women, and people who had previously used MK-8527 or a similar antiretroviral drug called islatravir, said Dr Kenneth Mayer, a professor of medicine at Harvard Medical School, who presented the findings in Kigali last week. The levels of the antiretroviral in the blood of all the participants were measured on day one and two, on the last day of taking the pill, and again at the first follow-up visit after stopping the pill. Based on these results, Mayer said there doesn't appear to be a build-up of drug in the body that might prove toxic over time. This supports evaluating the use of a monthly pill over a longer time period (than the six months in the study), he said, 'without concern that increasing drug levels will cause toxicity after a longer period of monthly administration'. About 20 participants across the three active pill arms were monitored more closely to measure the levels of MK-8527 triphosphate in their blood at each study visit. Results showed that the 6mg and 12mg doses kept levels at 'above the threshold of protection' for just more than 28 days. Apart from staying in the body for a long time, it also seems that the drug works very quickly. Mayer told delegates that modelling, informed by measurements of how the drug is taken up in the body, suggests that the pill could offer protection against HIV infection potentially as soon as an hour after taking it. How safe is it? Since HIV-prevention medicines are offered to healthy people, or at least people who are not living with HIV, the safety of these drugs is particularly closely watched. This is because the risk-benefit trade-off is different than it is for people who are living with HIV and might be willing to accept more side effects if it means the medicines are keeping them alive and healthy. The most common side effects reported in the phase-two study were headache, nausea and fatigue. The rates of these side effects were similar between participants who got the antiretroviral pills and those who got the placebo. One concerning event in the 3mg arm was a spontaneous abortion at six weeks into a pregnancy. According to Mayer, this was seen as a serious adverse event related to the study drug. He explained that although he didn't have all the details from the safety records, he understood that the participant had previously experienced pregnancy losses, but most if not all were induced. 'She did not have any other medical conditions that were associated with adverse pregnancy outcomes, so we had to consider the event related to the study medication, out of an abundance of caution, since this was a safety trial,' Mayer told Spotlight. Participants had tests done to check their CD4 levels (an indicator of immune system health) and lymphocyte (a type of white blood cell) counts at each study visit. A significant drop in either or both of these indicators would lead to the drug being stopped. Mayer explained that CD4 and lymphocyte counts were specifically monitored because the monthly pill has the same mechanism of action as another drug called islatravir, which in high doses resulted in a decrease in both these counts. 'MK-8527 is chemically different [to islatravir], but since they both inhibit these steps in the virus life cycle, it was important to monitor these parameters during the safety trial,' Mayer said. 'Fortunately, we did not see a significant trend affecting these clinical lab values.' Only two participants dropped out of the study because of side effects in the two higher dose groups. One person from the 12mg arm dropped out because of hypaesthesia, which is a loss of sensation or numbness. Another person in the 6mg arm left because their CD4 and/or lymphocyte count dropped to levels that met the study's rules for stopping the pill. In the next few years, the larger phase-three studies should provide much more extensive and detailed data on the safety and side effect profile of MK-8527. Is there a place for a monthly pill? At last year's Aids conference, delegates celebrated the success of the PURPOSE 1 and 2 trials that showed remarkable protection offered by lenacapavir, a long-acting HIV-prevention jab. It reliably offers protection against HIV infection for six months at a time. In June, it was approved for use by the US Food and Drug Administration for HIV prevention. It was previously approved only as treatment for hard-to-treat HIV. In July, the World Health Organization released guidelines recommending its use for HIV prevention. Lenacapavir has not yet been registered by the South African Health Products Regulatory Authority. Although most of the focus in HIV circles is still on lenacapavir, experts told Spotlight that even though MK-8527 may potentially only protect against HIV for about a month at a time, it could still be a useful option for HIV prevention. 'There is a real place for a long-acting, non-injectable PrEP [pre-exposure prophylaxis)]. And we believe there really is a role for a monthly pill – they are small [and] easy to take,' said Professor Linda-Gail Bekker, CEO of the Desmond Tutu Health Foundation and director of the Desmond Tutu HIV Centre. 'There is potential for giving all 12 pills in one go or three pills in one go, or any variation,' she added. This potential future option, provided it works, comes at a time when there is plenty of financial upheaval with the sudden termination of research funding and aid by the US. For Bekker, the hope is that a pill for prevention may prove to be an affordable and accessible option. Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition, told Spotlight that a monthly pill for prevention will not replace but add to the existing basket of HIV prevention options. 'It may help people who have a hard time adhering to daily pill-taking. It will help people who don't want to get an injection,' he said. 'It [MK-8527] is just 12 pills a year – that's a remarkable advance.' Next steps — the phase-three trials Merck, the pharmaceutical company that's developing the pill, announced that, later this year, MK-8527 will be evaluated at clinical trials sites across the globe in two large phase-three studies called EXPrESSIVE-10 and EXPrESSIVE-11. The studies will determine the safety and tolerability of the monthly pill, and whether it works as well as or better than the standard of care at preventing HIV. 'If MK-8527 is found to be comparable or superior to daily oral PrEP, it could be a game-changer for the HIV prevention field, offering people a simple way to protect themselves which would not require daily medication or injections,' said Mayer. Warren said that, like the PURPOSE studies, if a woman becomes pregnant during the study, she will have the option to give consent again and continue. This allows researchers to collect data on pregnant and breast-feeding women too. Although results from the phase-three studies are at least two years away, Merck appears set to try to roll out the product as soon as possible if it is successful. 'We are pursuing very optimistic and aggressive timelines,' said Dr Rebeca Plank, a scientist in clinical research at Merck, during an IAS press conference. DM This article first appeared in Spotlight.


The Citizen
2 days ago
- The Citizen
Measles outbreak in Gauteng: 181 cases confirmed, public urged to vaccinate
The Gauteng Department of Health has intensified its public health response following further measles cases across the province. Between January 1 and June 13, 181 laboratory-confirmed measles cases were reported, primarily in Johannesburg, Tshwane, and Ekurhuleni. In the latest reporting period, Gauteng recorded 15 new measles cases. Local nurse Nhlanhla Mofokeng explained what measles is and how to curb its spread. She defined measles as a highly contagious viral infection that mainly affects children but can infect anyone who is unvaccinated. 'It spreads through droplets in the air when an infected person coughs, sneezes, or talks. Measles symptoms appear about seven to 14 days after exposure,' she said. Signs and symptoms: • High fever; • Dry cough; • Runny nose; • Red, watery eyes; • Tiny white spots inside the mouth (Koplik spots); • A blotchy red rash that usually starts on the face and spreads downward. 'A person is contagious four days before and four days after the rash appears. Many people assume measles is just a rash and fever, but it can lead to severe complications,' she added. She mentioned these complications: • Pneumonia; • Diarrhoea and dehydration; • Ear infections (which might lead to hearing loss); • Brain swelling (encephalitis); • Death, especially in malnourished children or those with weakened immune systems. 'Children under five years, unvaccinated people of any age, people with weakened immune systems (HIV+ individuals) and pregnant women are at risk of contracting measles. 'Prevention is always better than cure. The measles vaccine is safe and free at public clinics across SA. It is given as part of the Measles, Mumps, and Rubella vaccine (MMR) at six months (extra dose during outbreaks), 12 months and 18 months,' she mentioned. Mofokeng said vaccination is the best protection because if enough people are vaccinated, the virus cannot spread; this is called herd immunity. She added that during the outbreak, people must ensure children are vaccinated by checking their Road-to-Health card. The nurse advised adults unsure of their vaccination status to visit a clinic for advice. 'If your child shows symptoms, keep them at home and visit a health facility immediately. Inform your school or crèche if a child was diagnosed. They may need to take steps to prevent further spread,' said Mofokeng. What to do if you suspect measles? • Step one: Seek medical care immediately; early detection can prevent serious illness. • Step two: Isolate the patient to avoid spreading the virus to others. • Step three: Follow the instructions from your clinic or doctor. ALSO READ: SASSA announces August payment dates for all social grants ALSO READ: Two arrested in Kwa-Thema for house robbery and possession of unlicensed firearms

IOL News
2 days ago
- IOL News
Mobile clinics bring life-saving cancer screening to rural communities
A groundbreaking partnership is bringing vital cancer screenings to South Africa's rural communities. Image: Supplied In South Africa, the challenge of healthcare access is a story of two halves. While urban centres have a network of hospitals and clinics, many rural communities face significant hurdles, often leading to late diagnoses for serious illnesses. This is especially true for cancer, where early detection can make all the difference. Non-communicable diseases (NCDs) are responsible for a staggering 65% of all natural causes of death in our country, a burden that the National Department of Health is working hard to reduce. It is in this context that a partnership is making a real difference: a collaboration between Rio Tinto, PinkDrive, and the National Department of Health to bring essential health screening directly to those who need it most. Starting in late July and running through August 2025, this initiative will see mobile healthcare screening clinics travelling through KwaZulu-Natal, the Eastern Cape, and the Northern Cape. This comes after a successful outreach in 2024, which laid the groundwork for this expanded mission. Werner Duvenhage, Managing Director of RTIT Africa Operations & RBM, shared his pride in the project, stating, 'We are proud to once again collaborate with PinkDrive to bring these services closer to those who need them most. Through this collaboration we can extend our reach and make a meaningful impact even in areas where we are not physically present. It is an extension of our core values.' The numbers from last year's outreach are impressive, with 7,695 people screened in just two weeks. This year, the goal is even more ambitious: to screen over 12,000 individuals and provide health education to many more. Noelene Kotschan, CEO and Founder of PinkDrive, highlighted the critical need for this type of service, explaining, 'Far too many South Africans are diagnosed late because they simply don't have access to screening facilities. Our model of mobile healthcare has proven both innovative and effective in bridging this gap.' PinkDrive's model is about bringing the healthcare facility to the community, using a fleet of mobile units to provide services that would otherwise be out of reach. The services offered are comprehensive and all provided at no cost. The mobile clinics will be staffed by a team of qualified doctors, nurses, radiographers, and health educators, offering everything from mammograms and pap smears to Prostate-Specific Antigen (PSA) tests, clinical breast examinations, and skin and lung cancer screenings. General health check-ups will also be available, with referrals to public health facilities arranged for anyone who needs further care. This initiative is a vital part of South Africa's national health goals, which focus on reducing the burden of NCDs through early detection, prevention, and improved access to care. The funding for this impactful project comes from the Rio Tinto Social Investment Fund, which is dedicated to creating lasting socio-economic benefits in the communities where the company operates. This collaboration is a powerful example of how public-private partnerships can directly improve health outcomes and bring essential services to the doorsteps of those who need them most, making a tangible difference in the lives of thousands of South Africans. IOL Lifestyle